Top Markets
#1 TENDIES TENDIES +31.34%
#2 ICON ICON +26.61%
#3 Cash Cat Cash Cat +22.92%
#4 Threshold Network Threshold Network +20.14%
#5 OSK OSK +15.74%
#6 Magma Finance Magma Finance +12.58%
#7 Asteroid Shiba Asteroid Shiba +12.44%
#8 Ape and Pepe Ape and Pepe +11.65%
#9 Kite Kite +11.54%
#10 龙虾 (Lobster) 龙虾 (Lobster) +10.56%
Coin of the day
TENDIES TENDIES
設定
言語
日本
通貨
USD
テーマ
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
株式のランク #16900
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
株価
$2.46
時価総額
$268.65M
変化（1日）
-1.73%
変化（1年）
-57.06%
国
CN
取引 VISEN Pharmaceuticals (2561)

カテゴリー

Healthcare
VISEN Pharmaceuticals（2561）の収益
Sep 2026 時点の収益 TTM: 0
VISEN Pharmaceuticals の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
VISEN Pharmaceuticals の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH